<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>While proper platelet function is a vital component of hemostasis, their inappropriate activation contributes to thrombotic disorders </plain></SENT>
<SENT sid="1" pm="."><plain>One pathway for platelet activation involves their synthesis of the <z:chebi fb="23" ids="18059">lipid</z:chebi> mediator <z:chebi fb="0" ids="26995">thromboxane</z:chebi> A₂ (<z:chebi fb="0" ids="36088">TXA</z:chebi>₂) </plain></SENT>
<SENT sid="2" pm="."><plain>Although <z:chebi fb="0" ids="36088">TXA</z:chebi>₂ acts by binding to a seven-transmembrane receptor (i.e., the <z:chebi fb="0" ids="26347">prostanoid</z:chebi> TP receptor) that participates in the genesis of <z:mp ids='MP_0005048'>thrombosis</z:mp>, currently, there are no <z:chebi fb="68" ids="48706">antagonists</z:chebi> available for clinical use </plain></SENT>
<SENT sid="3" pm="."><plain>Since the only available drug targeting this pathway (aspirin) is associated with inherent limitations/serious side effects, developing <z:chebi fb="0" ids="26347">prostanoid</z:chebi> TP receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> is clearly warranted </plain></SENT>
<SENT sid="4" pm="."><plain>To this end, we have previously employed the "repurposing old drugs for new uses" approach to identify <z:chebi fb="0" ids="26347">prostanoid</z:chebi> TP receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> and showed that the <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agent glybenclamide selectively inhibited human platelet <z:chebi fb="0" ids="26347">prostanoid</z:chebi> TP receptors (in vitro) </plain></SENT>
<SENT sid="5" pm="."><plain>On this basis, we hypothesized that glybenclamide exhibits in vivo antiplatelet potential, and therefore, may protect against <z:mp ids='MP_0005048'>thrombosis</z:mp> development </plain></SENT>
<SENT sid="6" pm="."><plain>Using murine platelets, it was found that glybenclamide injections: 1) inhibited platelet aggregation induced by the <z:chebi fb="0" ids="26347">prostanoid</z:chebi> TP receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> U46619 and the <z:chebi fb="0" ids="36088">TXA</z:chebi>₂ precursor <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi>, under ex vivo experimental settings, concentration-dependently; 2) lacked any detectable effects on aggregation stimulated by <z:chebi fb="13" ids="16761">ADP</z:chebi>, or the thrombin receptor activating-<z:chebi fb="7" ids="16670">peptide</z:chebi> 4; 3) <z:mp ids='MP_0009676'>impaired hemostasis</z:mp> by prolonging tail <z:mp ids='MP_0001914'>bleeding</z:mp> time; and 4) delayed the development of occlusive <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in a carotid artery injury model </plain></SENT>
<SENT sid="7" pm="."><plain>Taken together, these findings indicate that glybenclamide does indeed exert, ex vivo and in vivo, <z:chebi fb="0" ids="26347">prostanoid</z:chebi> TP receptor-dependent inhibitory effects on platelet function </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, glybenclamide has the potential to be applied in the management of thromboembolic disorders </plain></SENT>
</text></document>